Please login to the form below

Not currently logged in
Email:
Password:

Horizon Discovery appoints executive director

David Smoller is chief business officer at the genomics firm
david-smoller horizon

UK-based genetic research company Horizon Discovery has named Dr David Smoller as an executive director of the board.

Smoller joined Horizon as chief business officer as part of the form's acquisition of Sage Labs for $48m in September this year.

Of his appointment, he said: “The integration of Sage Labs and Horizon is progressing well and I am delighted to be joining the Horizon board at this exciting time for the company.”

His previous roles include the position of CEO at Sage Labs, chief scientific officer of Sigma-Aldrich and president of its research biotechnology business unit.

He also served as president of ProteoPlex, a seed stage spinout focusing on proteomics, which was acquired by Merck KGaA in 2003, and founded Genomes Systems, acquired by Incyte Genomics in 1996.

Horizon is a UK-based biotech focused on genomics research and the development of personalised medicines. It has partnerships with several major pharma companies, including AstraZeneca.

The company has undergone expansion in recent years with other senior appointments including GSK and Abbott veteran Dr Ian Gilham as chairman and the addition of AstraZeneca's head of oncology R&D Susan Galbraith to Horizon's board.

4th November 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics